What is Leerink Partnrs’ Estimate for KPTI FY2025 Earnings?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Equities researchers at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a report issued on Wednesday, February 19th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($0.75) for the year, down from their previous forecast of ($0.66). The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share.

Several other analysts also recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Piper Sandler boosted their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Royal Bank of Canada restated an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Finally, StockNews.com cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Trading Down 0.5 %

Karyopharm Therapeutics stock opened at $0.60 on Monday. The company has a market capitalization of $75.15 million, a price-to-earnings ratio of -0.58 and a beta of 0.06. Karyopharm Therapeutics has a 12 month low of $0.51 and a 12 month high of $1.70. The stock’s 50 day moving average is $0.66 and its 200-day moving average is $0.76.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. The company had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million.

Institutional Trading of Karyopharm Therapeutics

Institutional investors have recently modified their holdings of the stock. Velan Capital Investment Management LP acquired a new stake in Karyopharm Therapeutics during the fourth quarter worth about $27,000. Focus Partners Wealth acquired a new position in Karyopharm Therapeutics during the fourth quarter worth about $31,000. TD Waterhouse Canada Inc. bought a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at $32,000. Two Sigma Advisers LP increased its stake in shares of Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after buying an additional 45,400 shares during the period. Finally, Opti Capital Management LP bought a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $85,000. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).